IPCA Laboratories Ltd’s fundamental analysis highlights key financial metrics: Market Cap of ₹34,332.52 crore, PE Ratio of 62.72, Debt to Equity of 18.61, and Return on Equity of 8.02%. These indicators reflect the company’s financial health and market valuation.
Content:
- IPCA Laboratories Overview
- IPCA Laboratories Limited Financial Results
- IPCA Laboratories Ltd Financial Analysis
- IPCA Laboratories Limited Company Metrics
- IPCA Laboratories Ltd Stock Performance
- IPCA Laboratories Ltd Peer Comparison
- IPCA Laboratories Shareholding Pattern
- IPCA Laboratories Ltd History
- How To Invest In IPCA Laboratories Ltd Share?
- IPCA Laboratories Ltd Fundamental Analysis – FAQs
IPCA Laboratories Overview
IPCA Laboratories Ltd is an Indian pharmaceutical company manufacturing and marketing formulations and active pharmaceutical ingredients (APIs). It operates in the pharmaceutical sector, producing a wide range of medicines and APIs for various therapeutic segments.
The company is listed on both the NSE and BSE. With a market capitalisation of ₹34,332.52 crore, it’s currently 4.47% away from its 52-week high and 57.94% away from its 52-week low.
IPCA Laboratories Limited Financial Results
IPCA Laboratories Ltd demonstrated solid financial performance in FY 24, with sales increasing to ₹7,705 Crores from ₹6,244 Crores in FY 23. The company saw a rise in operating profit and maintained a consistent OPM, showcasing overall growth and financial stability.
1. Revenue Trend: Sales rose to ₹7,705 Crores in FY 24 from ₹6,244 Crores in FY 23, reflecting a robust revenue growth.
2. Equity and Liabilities: Equity capital remained stable at ₹25.37 Crores, with reserves increasing to ₹6,307 Crores. Total liabilities grew to ₹11,101 Crores from ₹8,626 Crores, indicating expansion.
3. Profitability: Operating profit improved to ₹1,321 Crores in FY 24 from ₹926.77 Crores in FY 23, with an OPM of 17%, up from 15%.
4. Earnings per Share (EPS): EPS rose to ₹25.82 in FY 24 from ₹18.58 in FY 23, signalling higher profitability per share.
5. Return on Net Worth (RoNW): RoNW saw an improvement, driven by increased profits and higher reserves, strengthening the company’s financial health.
6. Financial Position: Total assets increased to ₹11,101 Crores in FY 24 from ₹8,626 Crores in FY 23, supported by growth in both current and noncurrent assets.
IPCA Laboratories Ltd Financial Analysis
| FY 24 | FY 23 | FY 22 | |
| Sales | 7,705 | 6,244 | 5,830 |
| Expenses | 6,384 | 5,318 | 4,521 |
| Operating Profit | 1,321 | 927 | 1,309 |
| OPM % | 17 | 15 | 22 |
| Other Income | 17 | 126 | 67 |
| EBITDA | 1,446 | 1,052 | 1,376 |
| Interest | 138 | 46 | 8 |
| Depreciation | 357 | 262 | 232 |
| Profit Before Tax | 843 | 745 | 1,136 |
| Tax % | 37 | 34 | 20 |
| Net Profit | 523 | 479 | 890 |
| EPS | 25.82 | 18.58 | 34.85 |
| Dividend Payout % | 15.49 | 21.53 | 11.48 |
* Consolidated Figures in Rs. Crores
IPCA Laboratories Limited Company Metrics
IPCA Laboratories Ltd’s company metrics include a market capitalization of ₹34,332.52 crore, a book value per share of ₹250, and a face value of ₹1. With a debt-to-equity ratio of 18.61, a return on equity of 8.02%, and a 0.30% dividend yield, these figures underscore the company’s financial position and investment profile.
Market Capitalization: Market Capitalization represents the total market value of IPCA Laboratories’ outstanding shares, amounting to ₹34,332.52 crore.
Book Value: The book value per share of IPCA Laboratories is ₹250, indicating the value of the company’s net assets divided by its shares outstanding.
Face Value: The face value of IPCA Laboratories’ shares is ₹1, which is the original cost of the shares as stated on the certificate.
Asset Turnover Ratio: The asset turnover ratio of 0.80 measures how efficiently IPCA Laboratories uses its assets to generate revenue.
Total Debt: The total debt of ₹1,438.36 crore represents the sum of all short-term and long-term debt obligations of IPCA Laboratories.
Return on Equity (ROE): The ROE of 8.02% measures IPCA Laboratories’ profitability in generating income from its equity investments.
EBITDA (Q): The quarterly EBITDA of ₹413.33 crore represents IPCA Laboratories’ earnings before interest, taxes, depreciation, and amortization.
Dividend Yield: The dividend yield of 0.30% shows the annual dividend payment as a percentage of IPCA Laboratories’ current share price, indicating the return on investment from dividends alone.
IPCA Laboratories Ltd Stock Performance
IPCA Laboratories Ltd has delivered a 1-year return on investment of 56.4%, a 3-year return of 3.13% and a 5-year return of 23.6%. These returns reflect the company’s performance over different periods, showcasing strong short-term growth and moderate long-term gains.
| Period | Return on Investment (%) |
| 1 Year | 56.4 |
| 3 Years | 3.13 |
| 5 Years | 23.6 |
Example: If an investor had invested ₹1,000 in IPCA Laboratories’ stock:
1 year ago, their investment would be worth ₹1,564.
3 years ago, their investment would have grown to ₹1,031.30.
5 years ago, their investment would have increased to ₹1,236.
IPCA Laboratories Ltd Peer Comparison
IPCA Laboratories Ltd has a market cap of ₹34,332.52 Crores, a P/E ratio of 62.72 and an ROE of 18.61%. While its 1-year return of 52.56% is competitive, it lags behind peers like Zydus Lifesciences and Lupin in growth and efficiency metrics such as ROE and ROCE.
| Name | CMP Rs. | Mar Cap Rs.Cr. | P/E | ROE % | EPS 12M Rs. | 1Yr return % | ROCE % | Div Yld % |
| Sun Pharma.Inds. | 1761 | 422522.87 | 40.1 | 16.69 | 43.3 | 55.28 | 17.32 | 0.76 |
| Cipla | 1587.25 | 128179.88 | 28.88 | 16.79 | 53.3 | 28 | 22.8 | 0.84 |
| Zydus Lifesci. | 1208.85 | 121638.63 | 29.2 | 20.67 | 41.57 | 83.23 | 22.34 | 0.25 |
| Dr Reddy’s Labs | 7069.55 | 117962.19 | 21.17 | 21.39 | 333.63 | 17.55 | 26.53 | 0.56 |
| Lupin | 2113.15 | 96363.07 | 42.54 | 14.14 | 49.69 | 92.03 | 15.72 | 0.38 |
| Mankind Pharma | 2308 | 92466.56 | 49.33 | 19.71 | 48.12 | 27.46 | 24.57 | 0 |
| Aurobindo Pharma | 1503.2 | 88078.3 | 24.58 | 11.53 | 60.1 | 82.44 | 14.1 | 0.29 |
| IPCA Laboratories Ltd | 1353.25 | 34332.52 | 62.72 | 18.61 | 22.73 | 52.56 | 11.25 | 0.30 |
IPCA Laboratories Shareholding Pattern
IPCA Laboratories Ltd has maintained a stable promoter holding at 46.30% from March to June 2024. Foreign Institutional Investors (FII) increased their stake slightly to 10.85%, while Domestic Institutional Investors (DII) decreased their holding marginally to 33.78%. Retail investors’ participation remained relatively steady at 9.07%.
| All values in % | Jun-24 | Mar-24 | Dec-23 |
| Promoters | 46.30 | 46.30 | 46.29 |
| FII | 10.85 | 10.51 | 10.27 |
| DII | 33.78 | 34.37 | 34.51 |
| Retail & others | 9.07 | 8.82 | 8.93 |
IPCA Laboratories Ltd History
IPCA Laboratories Limited is a prominent Indian pharmaceutical company with a diverse product portfolio. The company manufactures and markets over 350 formulations and approximately 80 active pharmaceutical ingredients (APIs), covering various therapeutic segments to cater to a wide range of medical needs.
IPCA’s product range includes well-known APIs such as Atenolol, Chloroquine Phosphate and Hydroxychloroquine sulfate. The company has also established several successful brands in the market, including Zerodol, Lariago and Perinorm, which have gained recognition in the pharmaceutical industry.
With a global presence, IPCA’s products are sold in over 100 countries worldwide. The company operates 18 manufacturing units in India, producing both APIs and formulations. IPCA has further expanded its reach through subsidiaries like Ipca Pharmaceuticals, Inc., and IPCA Laboratories (U.K.) Ltd, and Tonira Exports Limited.
How To Invest In IPCA Laboratories Ltd Share?
To invest in IPCA Laboratories shares, open a demat account with Alice Blue. Research the company’s fundamentals, financial performance, and position in the pharmaceutical industry. Analyze historical stock data and compare it with industry peers.
Determine your investment strategy based on your financial goals and risk tolerance. Consider factors such as the company’s product portfolio, research and development pipeline and global market presence. Decide on the investment amount and timing.
Place your order through the broker’s platform. Regularly monitor your investment, staying updated on company news, quarterly results and pharmaceutical industry trends. Consider seeking advice from a financial advisor for personalized guidance and to ensure your investment aligns with your overall portfolio strategy.
IPCA Laboratories Ltd Fundamental Analysis – FAQs
IPCA Laboratories Ltd’s fundamental analysis reveals a Market Cap of ₹34,332.52 crore, PE Ratio of 62.72, Debt to Equity of 18.61, and Return on Equity of 8.02%. These metrics provide insights into the company’s financial health, profitability, and market valuation.
IPCA Laboratories Ltd’s market capitalization is ₹34,332.52 crore. This figure represents the total value of the company’s outstanding shares in the stock market, calculated by multiplying the current stock price by the number of outstanding shares.
IPCA Laboratories Limited is an Indian pharmaceutical company that manufactures and markets a wide range of formulations and active pharmaceutical ingredients (APIs). It produces over 350 formulations and 80 APIs, covering various therapeutic segments and selling products globally.
4. Who Is The Owner Of IPCA Laboratories?
IPCA Laboratories is a public limited company with diverse ownership. The promoter group, including the Vora family, holds a significant stake. As a listed entity, ownership is distributed among various institutional and individual shareholders through stock market participation.
The main shareholders of IPCA Laboratories Ltd include the promoter group (Vora family), institutional investors, and public shareholders. For the most current and accurate information on major shareholders, refer to the company’s latest shareholding pattern disclosure.
IPCA Laboratories Limited is an Indian pharmaceutical company that manufactures and markets a wide range of formulations and active pharmaceutical ingredients (APIs). It produces over 350 formulations and 80 APIs, covering various therapeutic segments and selling products globally.
IPCA Laboratories is a public limited company with diverse ownership. The promoter group, including the Vora family, holds a significant stake. As a listed entity, ownership is distributed among various institutional and individual shareholders through stock market participation.
The main shareholders of IPCA Laboratories Ltd include the promoter group (Vora family), institutional investors, and public shareholders. For the most current and accurate information on major shareholders, refer to the company’s latest shareholding pattern disclosure.
Determining if IPCA Laboratories is a good stock to buy depends on various factors including its financial performance, growth prospects, and industry trends. Analyze the company’s fundamentals, compare with peers, and consider your investment goals. Consult a financial advisor for personalized advice.
IPCA Laboratories operates in the pharmaceutical industry. The company specializes in manufacturing and marketing a wide range of formulations and active pharmaceutical ingredients (APIs), catering to various therapeutic segments in both domestic and international markets.
To invest in IPCA Laboratories shares, open a demat account with Alice Blue. Research the company’s performance and pharmaceutical industry trends. Decide on your investment strategy. Place your order through the broker’s platform. Regularly monitor your investment, staying informed about market conditions. Consider seeking financial advice for personalized guidance.
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.
